These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30685396)

  • 1. Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice.
    Al-Shammari AH; Masuo Y; Fujita KI; Yoshikawa Y; Nakamichi N; Kubota Y; Sasaki Y; Kato Y
    J Pharm Sci; 2019 Jun; 108(6):2173-2179. PubMed ID: 30685396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites.
    Fujita KI; Masuo Y; Yamazaki E; Shibutani T; Kubota Y; Nakamichi N; Sasaki Y; Kato Y
    J Pharm Sci; 2017 Sep; 106(9):2632-2641. PubMed ID: 28479358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
    Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolome Analysis Reveals Dermal Histamine Accumulation in Murine Dermatitis Provoked by Genetic Deletion of P-Glycoprotein and Breast Cancer Resistance Protein.
    Hashimoto N; Nakamichi N; Nanmo H; Kimura KI; Masuo Y; Sakai Y; Schinkel AH; Sato S; Soga T; Kato Y
    Pharm Res; 2019 Sep; 36(11):158. PubMed ID: 31512001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
    Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
    Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients.
    Kubota Y; Fujita KI; Takahashi T; Sunakawa Y; Ishida H; Hamada K; Ichikawa W; Tsunoda T; Shimada K; Masuo Y; Kato Y; Sasaki Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):586-595. PubMed ID: 32034953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate.
    Hashimoto N; Nakamichi N; Uwafuji S; Yoshida K; Sugiura T; Tsuji A; Kato Y
    J Control Release; 2013 Jan; 165(1):54-61. PubMed ID: 23089896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
    Agarwal S; Elmquist WF
    Mol Pharm; 2012 Mar; 9(3):678-84. PubMed ID: 22335402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
    Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
    Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-associated virus-mediated knockdown demonstrates the major role of hepatic Bcrp in the overall disposition of the active metabolite of the tyrosine kinase inhibitor regorafenib in mice.
    Alshammari AH; Masuo Y; Yoshino S; Yamashita R; Ishimoto T; Fujita KI; Kato Y
    Drug Metab Pharmacokinet; 2023 Apr; 49():100483. PubMed ID: 36724604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.
    Wang J; Bruin MAC; Gan C; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
    Int J Pharm; 2020 May; 581():119277. PubMed ID: 32234426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mdr1a, Bcrp and Mrp2 regulate the efficacy and toxicity of mesaconitine and hypaconitine by altering their tissue accumulation and in vivo residence.
    Li X; Ou X; Luo G; Ou X; Xie Y; Ying M; Qu W; Zuo H; Qi X; Wang Y; Liu Z; Zhu L
    Toxicol Appl Pharmacol; 2020 Dec; 409():115332. PubMed ID: 33171190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
    Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
    Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
    Miyake T
    Biol Pharm Bull; 2020 Mar; 43(3):384-392. PubMed ID: 31685755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical administration of regorafenib eye drops: phase I dose-escalation study in healthy volunteers.
    Zimmermann T; Höchel J; Becka M; Boettger MK; Rohde B; Schug B; Kunert KS; Donath F
    Br J Clin Pharmacol; 2018 May; 84(5):865-875. PubMed ID: 29315699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.